Would you use 6 months (instead of 12 months) of trastuzumab for locally advanced Her-2 positive breast cancer patients?   

Would you do this for ER+ patients?

According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Herceptin is non-inferior to 12 months of trastuzumab. Subgroup analysis showed benefit in ER positive group.



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution